SGLT2 Inhibitors as a Therapeutic Option for Diabetic Nephropathy

SGLT2 Inhibitors as a Therapeutic Option for Diabetic Nephropathy

Diabetic nephropathy (DN) is a major cause of end-stage renal disease (ESRD) worldwide. Glycemic and blood pressure (BP) control are important but not sufficient to attenuate the incidence and progression of DN. Sodium–glucose cotransporter (SGLT) 2 inhibitors are a new class of glucose-lowering age...

Full description

Bibliographic Details
Main Authors: Daiji Kawanami, Keiichiro Matoba, Yusuke Takeda, Yosuke Nagai, Tomoyo Akamine, Tamotsu Yokota, Kazunori Sango, Kazunori Utsunomiya
Format: Article
Language:English
Published: MDPI AG 2017-05-01
Series:International Journal of Molecular Sciences
Subjects:
diabetic nephropathy
cardiovascular disease
SGLT2 inhibitors
Online Access:http://www.mdpi.com/1422-0067/18/5/1083

Internet

http://www.mdpi.com/1422-0067/18/5/1083

Similar Items